Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Ettle

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Neurochemistry|July 24, 2015
Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's diseaseJanina Deusser, Stefanie Schmidt, Benjamin Ettle, et al.
Frontiers in Neurology|March 25, 2021
Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS PatientsTjalf Ziemssen, Holger Albrecht, Judith Haas, et al.
Acta Neuropathologica|February 11, 2014
Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PDSilke Nuber, Daniel Tadros, Jerel Fields, et al.
Multiple Sclerosis and Related Disorders|December 23, 2019
Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumabTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Molecular and Cellular Neurosciences|July 15, 2014
Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cellsBenjamin Ettle, Simone Reiprich, Janina Deusser, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 4, 2022
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in GermanyDominik Koeditz, Juergen Frensch, Martin Bierbaum, et al.
Brain Pathology (Zurich, Switzerland)|November 17, 2018
Oligodendroglial α-synucleinopathy-driven neuroinflammation in multiple system atrophyAlana Hoffmann, Benjamin Ettle, Kristina Battis, et al.
Biochemical and Biophysical Research Communications|September 27, 2016
Alpha-synuclein activates BV2 microglia dependent on its aggregation stateAlana Hoffmann, Benjamin Ettle, Ariane Bruno, et al.
Neurobiology of Aging|April 5, 2014
α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophyVerena E L May, Benjamin Ettle, Anne-Maria Poehler, et al.
The American Journal of Pathology|January 15, 2013
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinDora Games, Peter Seubert, Edward Rockenstein, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Neurochemistry|July 24, 2015
Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's diseaseJanina Deusser, Stefanie Schmidt, Benjamin Ettle, et al.
Frontiers in Neurology|March 25, 2021
Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS PatientsTjalf Ziemssen, Holger Albrecht, Judith Haas, et al.
Acta Neuropathologica|February 11, 2014
Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PDSilke Nuber, Daniel Tadros, Jerel Fields, et al.
Multiple Sclerosis and Related Disorders|December 23, 2019
Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumabTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Molecular and Cellular Neurosciences|July 15, 2014
Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cellsBenjamin Ettle, Simone Reiprich, Janina Deusser, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 4, 2022
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in GermanyDominik Koeditz, Juergen Frensch, Martin Bierbaum, et al.
Brain Pathology (Zurich, Switzerland)|November 17, 2018
Oligodendroglial α-synucleinopathy-driven neuroinflammation in multiple system atrophyAlana Hoffmann, Benjamin Ettle, Kristina Battis, et al.
Biochemical and Biophysical Research Communications|September 27, 2016
Alpha-synuclein activates BV2 microglia dependent on its aggregation stateAlana Hoffmann, Benjamin Ettle, Ariane Bruno, et al.
Neurobiology of Aging|April 5, 2014
α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophyVerena E L May, Benjamin Ettle, Anne-Maria Poehler, et al.
The American Journal of Pathology|January 15, 2013
Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synucleinDora Games, Peter Seubert, Edward Rockenstein, et al.
Pageof 3